Search and Filter Protocols

Use the checkboxes and search input field to locate the relevant protocol.

To filter by categories, simply select the relevant categories and/or statuses and click "submit" (without entering any text into the search field).

To search by Protocol name, simply enter it into the search box and click "submit".

  • Disease Categories

*NOTE* if there are categories that have no protocols attached, they will not show up as a checkbox for filtering. For example, if "Head and Neck" is not available as a disease category checkbox selection, there are no protocols that have that disease category assigned.

All Current Protocols Arranged Alphabetically by Disease Category:

Brain

ALLIANCE A071401

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations

NCT#02523014

A071401 Cohorts NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) will close to new patient registration (Step 1) to abemaciclib cohort, effective October 3, 2022

ALLIANCE A071601

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

 

NCT#03224767

ALLIANCE A071701

Primary Category:

Treatment Protocols

Disease Category:

Brain, Brain Metastatic, Molecular Profiling

Status:

Open

Genomically-Guided Treatment Trial in Brain Metastases

ALLIANCE A071702

Primary Category:

Treatment Protocols

Disease Category:

Brain

Status:

Open

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

NCT#04145115

ALLIANCE A071801

Primary Category:

Radiation Oncology

Disease Category:

Brain, Brain Metastatic

Status:

Open

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Eligible for screening study DCP 001

NCT#04114981

A071801 Pre-registration (Step 0) is closed to accrual, effective September 9, 2022 at 4:30 pm ET.

ALLIANCE CCTG CE.7

Primary Category:

Radiation Oncology

Disease Category:

Brain, Brain Metastatic

Status:

Open

A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases

Eligible for screening study DCP 001

For CCTG CE.7, please credit ALLIANCE all accruals.

NCT#03550391

CCTG CE.7 has reopened with Amendment 1 to resume patient accrual at your center, your site will be required to provide confirmation of HA-WBRT credentialing and approval by IROC.

Protocol     Consent     Schema     Eligibility & Calendar

ALLIANCE N0577

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Eligible for screening study DCP 001

NCT#00887146

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG BN003

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Eligible for screening study DCP 001

NCT#03180268

 

NRG BN007

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Temporarily Closed

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

NCT#04396860

BN007 is temporarily closed to accrual effective April 27, 2022 at 5pm ET.

NRG BN010

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain

Status:

Open

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

NCT#04729959

BN010 is reopened to accrual to the safety run-in, dose level 2, effective September 26, 2022.

BN010, safety run in, dose level 1, is closed to accrual, effective June 29, 2022.

 

NRG CC009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain, Lung, Lung - Small Cell

Status:

Open

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

Eligible for screening study DCP 001

NCT#04804644

 

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Breast

AFT-25 COMET

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Breast, Breast DCIS

Status:

Open

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial

NCT#02926911

Limited institution study – Only open to:  Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.

Sites must submit to MCC a protocol specific Training Log and an AFT Delegation of Authority Log before any patient registrations may take place.

Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.

ALLIANCE A011801

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Eligible for screening study DCP 001

NCT#04457596

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A191901

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Eligible for screening study DCP 001

NCT#04379570

A191901 is permanently closed to accrual of non-Black women over 50, effective February 25, 2022 at 4:30pm (ET)

A191901 is permanently closed to accrual of non-Black women, effective April 15, 2022 at 4:30pm (ET)

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ALLIANCE A221803

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

New, Open

Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial

NCT#04989504

Eligible for screening study DCP 001

ECOG-ACRIN EA1151

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast

Status:

Open

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Limited institution study: open only to Saint Alphonsus Health System.

NCT#03233191

Eligible for screening study DCP 001

 

 

ECOG-ACRIN EA1181

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

Open

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022

NCT#04266249

ECOG-ACRIN EA1183

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE

NCT#04316117

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG BR005

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

Temporarily Closed

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery

NCT#03188393

Effective today, July 2, 2019, study NRG BR005 is temporarily closed to accrual.

NRG BR007

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Breast

Status:

Open

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score

NCT#04852887

Eligible for screening study DCP 001

 

NRG CCTG MA.39

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

Eligible for screening study DCP 001

For CCTG MA.39, please credit NRG all accruals.

CCTG MA.39-Optional Questionnaire Component is closed to accrual effective August 2, 2022

NCT#03488693

SWOG S1501

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Eligible for screening study DCP 001

NCT#03418961

S1501,  Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S1703

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

NCT#03723928

Eligible for screening study DCP 001

SWOG S1706

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Open

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

NCT#03598257

SWOG S2007

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

NCT#04647916

 

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Cancer Care Delivery

SWOG S1912CD

Primary Category:

Cancer Care Delivery

Disease Category:

Cancer Care Delivery

Status:

Open

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

Eligible for screening study DCP 001

NCT#04960787

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Gastrointestinal

ALLIANCE A021502

Primary Category:

Treatment Protocols

Disease Category:

Colon, Gastrointestinal

Status:

Open

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Eligible for screening study DCP 001

NCT#02912559

Site Delegation of Tasks Log required prior to registration of any patients.

ALLIANCE A021602

Primary Category:

Treatment Protocols

Disease Category:

Carcinoid, Neuroendocrine, Pancreatic

Status:

Open

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

NCT#03375320

Eligible for screening study DCP 001

ALLIANCE A021703

Primary Category:

Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic

Status:

Open

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Eligible for screening study DCP 001

NCT#04094688

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ALLIANCE A221805

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Colon, Gastrointestinal, Rectal

Status:

Open

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Eligible for screening study DCP 001

A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET

NCT#04137107

ECOG-ACRIN EA2176

Primary Category:

Treatment Protocols

Disease Category:

Anal, Gastrointestinal

Status:

Open

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

Eligible for screening study DCP 001

NCT#04444921

 

 

 

ECOG-ACRIN EA2182

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Anal, Gastrointestinal

Status:

Open

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

NCT#04166318

ECOG-ACRIN EA2183

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Esophageal, Esophageal Metastatic, Gastrointestinal, Stomach, Stomach Metastatic

Status:

Open

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

NCT#04248452

Eligible for screening study DCP 001

EA2183 is reopened to accrual with the implementation of Amendment 2, effective April 5, 2022

ECOG-ACRIN EA2186

Primary Category:

Surgical Protocols, Treatment Protocols

Disease Category:

Gastrointestinal, Pancreatic Metastatic

Status:

Open

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

NCT#04233866

ECOG-ACRIN EA2187

Primary Category:

Treatment Protocols

Disease Category:

Cholangiocarcinoma, Gastrointestinal

Status:

Temporarily Closed

A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

 

NCT#04175912

EA2187 is temporarily closed to patient accrual effective March 31, 2021.

ECOG-ACRIN EA2201

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Gastrointestinal, Rectal

Status:

Open

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

NCT#04751370

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG GI004

Primary Category:

Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic

Status:

Open

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Eligible for screening study DCP 001

NRG GI004 reopened to accrual effective January, 29, 2021.

NCT#02997228

Site Delegation of Tasks Log required prior to registration of any patients.

NRG GI005

Primary Category:

Treatment Protocols

Disease Category:

Colon, Gastrointestinal

Status:

Open

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

NCT#04068103

GI005 is reopened upon implementation of Amendment 1, effective June 15, 2021.

NRG GI008

Primary Category:

Treatment Protocols

Disease Category:

Colon

Status:

New, Open

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

NCT#05174169

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S1922

Primary Category:

Treatment Protocols

Disease Category:

Gastrointestinal, Small Bowel

Status:

Open

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

NCT#04205968

SWOG S2001

Primary Category:

Treatment Protocols

Disease Category:

Pancreatic, Pancreatic Metastatic

Status:

Open

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

NCT#04548752

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2107

Primary Category:

Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Rectal, Rectal Metastatic

Status:

New, Open

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

NCT#05308446

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Genitourinary

ALLIANCE A031102

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary

Status:

Open

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Eligible for screening study DCP 001

A031102 will permanently close to accrual, effective October 26, 2022.

NCT#02375204

ALLIANCE A031701

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

NCT#03609216

ALLIANCE A031702

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary, Prostate, Renal

Status:

Open

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

NCT#03866382

 

ALLIANCE A031704

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Renal, Renal Metastatic

Status:

Open

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Eligible for screening study DCP 001

NCT#03793166

A031704 is reactivated to new patient registration (Step 1), effective March 26, 2021.

ALLIANCE A031801

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Renal, Renal Metastatic

Status:

Open

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)

NCT#04071223

ALLIANCE A031803

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NCT#04164082

Effective 09/30/20, new patient registration (Step 1) of A031803 is reopened to accrual.

ALLIANCE A031902

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate Metastatic

Status:

Open

CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Eligible for screening study DCP 001

A031902 is reactivated to new patient enrollment, effective  July 27, 2021.

NCT#04455750

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ALLIANCE A222001

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

Eligible for screening study DCP 001

NCT#04600336

 

ECOG-ACRIN EA8171

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

NCT#03697148

ECOG-ACRIN EA8183

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Eligible for screening study DCP 001

NCT#04484818

 

ECOG-ACRIN EA8185

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)

NCT#04216290

 

ECOG-ACRIN EA8191

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Eligible for screening study DCP 001

NCT#04423211

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG GU007

Primary Category:

Radiation Oncology

Disease Category:

Genitourinary, Prostate

Status:

Open

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I)

NCT#04037254

GU007 is reopened to accrual to phase I/dose level 3, effective September 26, 2022.

GU007 Phase II is not open to accrual as of January 27, 2022.

NRG GU008

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Genitourinary, Prostate

Status:

Open

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy

NCT#04134260

Eligible for screening study DCP 001

GU008 is reopened to accrual upon implementation of Amendment 2, effective December 7, 2021.

NRG GU009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Prostate

Status:

Open

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

Eligible for screening study DCP 001

Optional Imaging Sub Study is temporarily closed accrual, effective December 21, 2021

NCT#04513717

NRG GU010

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Prostate

Status:

Open

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)

NCT#05050084

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S1802

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Genitourinary, Prostate, Prostate Metastatic

Status:

Open

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

NCT#03678025

Eligible for screening study DCP 001

SWOG S1806

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

NCT#03775265

Eligible for screening study DCP 001

SWOG S1937

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary

Status:

Open

A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Eligible for screening study DCP 001

NCT#04579224

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Gynecologic

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG CC008

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Ovarian

Status:

Open

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]

 

Eligible for screening study DCP 001

NCT#04251052

NRG GY012

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Endometrial Metastatic, Gynecologic

Status:

Open

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

NCT#03660826

GY012 is reopened to accrual, effective May 23, 2022.

 

NRG GY018

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Gynecologic

Status:

Open

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer

Eligible for screening study DCP 001

GY018 is no longer open to registration of dMMR patient population, effective August 15, 2022. Accrual of pMMR patients will continue.

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.

NCT#03914612

NRG GY019

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian, Ovarian Metastatic

Status:

Open

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Eligible for screening study DCP 001

NCT#04095364

NRG GY023

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian

Status:

Open

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

NCT#04739800

 

NRG GY024

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

GYN Other, Gynecologic

Status:

Open

Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial

NCT#05076942

NRG GY026

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Endometrial Metastatic, Gynecologic

Status:

New, Open

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

NCT#05256225

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Head and Neck

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EA3161

Primary Category:

Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC

NCT#03811015

ECOG-ACRIN EA3163

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a (and selected T4b) nasal and paranasal sinus squamous cell carcinoma (NPNSCC)

NCT#03493425

Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21

ECOG-ACRIN EA3191

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

NCT#04671667

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG HN005

Primary Category:

Radiation Oncology

Disease Category:

Head and Neck

Status:

Open

A Randomized Phase II/II Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Open to Phase II enrollment

NCT#03952585

NRG R1216

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Head and Neck

Status:

Open

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

NCT#01810913

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Leukemia

ALLIANCE A041501

Primary Category:

Treatment Protocols

Disease Category:

Acute Lymphocytic Leukemia, Leukemia

Status:

Temporarily Closed

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

NCT#03150693

Eligible for screening study DCP 001

Temporary suspension effective May 24, 2022 due to Alliance DSMB review.

Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018.  See Section 4.4 for registration and randomization instructions.

ALLIANCE A041701

Primary Category:

Treatment Protocols

Disease Category:

Acute Myeloid Leukemia, Leukemia

Status:

Temporarily Closed

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

NCT#03701308

A041701, pre-registration (Step 0) is temporarily closed to accrual, effective November 19, 2021 at 4:30 PM ET.

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EA9171

Primary Category:

Treatment Protocols

Disease Category:

Chronic Myeloid Leukemia, Leukemia

Status:

Open

BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD

NCT#03516279

ECOG-ACRIN NHLBI-MDS

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Leukemia, Myelodysplastic Syndrome

Status:

Open

The National Myelodysplastic Syndromes (MDS) Study

 

NCT#02775383

Eligible for screening study DCP 001

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.

Suspension to enrollment of new participants and follow-up research sample collection and shipment is lifted effective May 18, 2020, for NHLBI-MDS.  Refer to memo dated March 27, 2020, on conducting remote follow-up data for enrolled participants.

SWOG S1712

Primary Category:

Treatment Protocols

Disease Category:

Chronic Myeloid Leukemia, Leukemia

Status:

Open

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

NCT#03654768

SWOG S1925

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Lymphoma

Status:

Open

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Eligible for screening study DCP 001

NCT#04269902

 

Lung

ALLIANCE A081801

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

A081801 is reopened to accrual, effective March 15, 2022, upon implementation of Update 7

(See required screening study ALLIANCE A151216)

NCT#04267848

ALLIANCE A151216

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801E4512, and EA5142 (closed).

Eligible for screening study DCP 001

Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.

NCT#02194738

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A171901

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist’s/Patient’s Choice)

Eligible for screening study DCP 001

NCT#04533451

 

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN E4512

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

(See required screening study ALLIANCE A151216)

Eligible for screening study DCP 001

NCT#02201992

Additional Documents

 

ECOG-ACRIN EA5162

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Temporarily Closed

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

NCT#03191149

Effective July 2, 2019, study EA5162 is temporarily closed to accrual.

ECOG-ACRIN EA5163

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

NCT#03793179

Eligible for screening study DCP 001

ECOG-ACRIN EA5181

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Eligible for screening study DCP 001

NCT#04092283

ECOG-ACRIN EA5182

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Eligible for screening study DCP 001

NCT#04181060

ECOG-ACRIN EA5191

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell Metastatic

Status:

Open

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

NCT#04310007

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG CC009

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Brain, Lung, Lung - Small Cell

Status:

Open

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

Eligible for screening study DCP 001

NCT#04804644

 

NRG LU002

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Temporarily Closed

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

NCT#03137771

LU002 is temporarily closed to accrual, effective November 12, 2021.

 

 

NRG LU007

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage

Status:

Open

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

NCT#04402788

 

SWOG 1800D

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell Metastatic

Status:

Open

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

See Screening Protocol LUNGMAP

NCT#05096663

SWOG LUNGMAP

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

NCT#03851445

Eligible for screening study DCP 001

Effective, June 30th, 2019, the sub-study S1400GEN is closed to accrual.

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S1827

Primary Category:

Radiation Oncology

Disease Category:

Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage

Status:

Open

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Eligible for screening study DCP 001

NCT#04155034

SWOG S1900E

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic

Status:

Open

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

See Screening Protocol LUNGMAP

S1900E reopened to accrual effective May 26, 2021.

NCT#04625647

 

SWOG S1900F

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell Metastatic

Status:

New, Open

A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)

See Screening Protocol LUNGMAP

NCT#05364645

SWOG S1914

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Eligible for screening study DCP 001

NCT#04214262

SWOG S1929

Primary Category:

Treatment Protocols

Disease Category:

Lung - Small Cell Extensive Stage

Status:

Open

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

S1929, Step 1 Screening Registration is permanently closed to accrual, effective August 15, 2022, at 3:45am PT.  Step 2 Randomization remains open until further notice.

NCT#04334941

SWOG S1933

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Lung - Non-Small Cell

Status:

Open

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

 

NCT#04310020

SWOG S1934

Primary Category:

Radiation Oncology, Surgical Protocols, Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell

Status:

Open

NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer

NCT#04989283

S1934 is reopened to accrual upon implementation of Revision 1, effective March 1, 2022.

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Lymphoma

ALLIANCE A021602

Primary Category:

Treatment Protocols

Disease Category:

Carcinoid, Neuroendocrine, Pancreatic

Status:

Open

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

NCT#03375320

Eligible for screening study DCP 001

ALLIANCE A051301

Primary Category:

Treatment Protocols

Disease Category:

Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

Eligible for screening study DCP 001

NCT#02443077

This study is open to FACT-accredited institutions only.

Site Delegation of Tasks Log required prior to registration of any patients.

ALLIANCE A051701

Primary Category:

Treatment Protocols

Disease Category:

Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Status:

Temporarily Closed

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

NCT#03984448

A051701 is temporarily closed to accrual effective August 2, 2021.

A051701 accrual of patients with double expressing lymphoma (DEL) is temporarily halted effective August 2, 2021.

A051701 accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted effective September 28, 2020.

 

 

ALLIANCE A051902

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

NCT#04803201

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EA4151

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

NCT#03267433

Eligible for screening study DCP 001

Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21

ECOG-ACRIN EA4181

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma

Status:

Open

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma

NCT#04115631

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

SWOG S1608

Primary Category:

Treatment Protocols

Disease Category:

Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

Status:

Temporarily Closed

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

S1608 is temporarily closed to accrual, effective February 9, 2022 at 1:00pm Pacific Time

NCT#03269669

SWOG S1826

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Hodgkin Lymphoma, Lymphoma

Status:

Open

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

NCT#03907488

Eligible for screening study DCP 001

 

SWOG S1925

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Lymphoma

Status:

Open

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Eligible for screening study DCP 001

NCT#04269902

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

Molecular Profiling

ALLIANCE A071701

Primary Category:

Treatment Protocols

Disease Category:

Brain, Brain Metastatic, Molecular Profiling

Status:

Open

Genomically-Guided Treatment Trial in Brain Metastases

ALLIANCE A151216

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801E4512, and EA5142 (closed).

Eligible for screening study DCP 001

Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.

NCT#02194738

ECOG-ACRIN E4512

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Molecular Profiling

Status:

Open

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

(See required screening study ALLIANCE A151216)

Eligible for screening study DCP 001

NCT#02201992

Additional Documents

 

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

ECOG-ACRIN EAY131-H

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Open

MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)

 

(See required screening study ECOG-ACRIN EAY131)

EAY131-H has expanded its accrual goal, therefore it is reactivated effective 10/02/2020.

NCT#02465060

ECOG-ACRIN EAY131-J

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

(See required screening study ECOG-ACRIN EAY131)

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

Effective June 14, 2019, sub-study EAY131-J is temporarily closed to accrual.

NCT#02465060

ECOG-ACRIN EAY131-K2

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions

(See required screening study ECOG-ACRIN EAY131)

Open  to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

Effective today, July 18th, 2019, Subprotocol K2: Phase 2 is suspended due to the completion of accrual.

NCT#02465060

ECOG-ACRIN EAY131-M

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

(See required screening study ECOG-ACRIN EAY131)

EAY131 Subprotocol M is temporarily closed to accrual, effective August 3, 2021

Open  to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

NCT#02465060

ECOG-ACRIN EAY131-Z1M

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy

(See required screening study ECOG-ACRIN EAY131)

Accrual to EAY131-Z1M is suspended, effective September 27, 2022.

NCT#02465060

 

 

SWOG S1609

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Open

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

NCT#02834013

Eligible for screening study DCP 001

Please see http://www.swogstat.org/accrual/dart.htm for up-to-date accrual information and current cohort accrual status (i.e. open, closed, suspended).  The website is updated with the most current information daily.

 

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Multiple Myeloma

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EA1183

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE

NCT#04316117

 

ECOG-ACRIN EAA173

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Open

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Eligible for screening study DCP 001

NCT#03937635

ECOG-ACRIN EAA181

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Open

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Eligible for screening study DCP 001

NCT#04566328

 

SWOG S1501

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Eligible for screening study DCP 001

NCT#03418961

S1501,  Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.

SWOG S1703

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

NCT#03723928

Eligible for screening study DCP 001

SWOG S1803

Primary Category:

Treatment Protocols

Disease Category:

Multiple Myeloma

Status:

Open

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Eligible for screening study DCP 001

Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents and for any questions.

NCT#04071457

SWOG S2007

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

Open

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

NCT#04647916

 

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

Neuroendocrine

ALLIANCE A021602

Primary Category:

Treatment Protocols

Disease Category:

Carcinoid, Neuroendocrine, Pancreatic

Status:

Open

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

NCT#03375320

Eligible for screening study DCP 001

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Other

ALLIANCE A032002

Primary Category:

Radiation Oncology, Treatment Protocols

Disease Category:

Other

Status:

Open

Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

NCT#04936230

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

DCP 001

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Other

Status:

Open

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

ECOG-ACRIN EA1181

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

Open

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022

NCT#04266249

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

NRG BR005

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

Temporarily Closed

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery

NCT#03188393

Effective today, July 2, 2019, study NRG BR005 is temporarily closed to accrual.

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S1701

Primary Category:

Treatment Protocols

Disease Category:

Other

Status:

Open

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

NCT#03694002

S1701 will permanently close to accrual, effective October 15, 2022, at 12pm PT.

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Sarcoma

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Skin

ALLIANCE A091802

Primary Category:

Treatment Protocols

Disease Category:

Skin

Status:

Open

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)

NCT#03944941

ALLIANCE A091903

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

New, Open

A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma

NCT#05111574

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

ECOG-ACRIN EA6141

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

NCT#02339571

This protocol has additional training requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.

Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21

Additional Documents

 

ECOG-ACRIN EA6174

Primary Category:

Treatment Protocols

Disease Category:

Skin

Status:

Open

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

NCT#03712605

Eligible for screening study DCP 001

ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)

 

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2000

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin

Status:

Open

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

NCT#04511013

 

SWOG S2013

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic

Status:

Open

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligible for screening study DCP 001

NCT#04871542

 

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606

Solid tumor or Hematologic Malignancy

ECOG-ACRIN EAQ172

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Solid tumor or Hematologic Malignancy

Status:

Open

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Eligible for screening study DCP 001

NCT#04438382

Thyroid

ALLIANCE A151804

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Open

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

NCT#04242095

ALLIANCE A212102

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid

Status:

New, Open

Blinded Reference Set For Multicancer Early Detection Blood Tests

NCT#05334069

SWOG S1614

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

Temporarily Closed

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Eligible for screening study DCP 001

NCT#03887702

S1614 is temporarily closed to accrual, effective September 8, 2022.

SWOG S2108CD

Primary Category:

Cancer Care Delivery

Disease Category:

Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid

Status:

New, Open

A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy

Limited site participation.  Open only to Kootenai Cancer Center.

NCT#05455606